Elevated fasting glucose is common in lung cancer patients undergoing 18F-FDG PET/CT: A brief report

Key Points

• Lung cancer patients exhibit elevated fasting glucose levels, impacting their metabolic profile.
• Informed by assessments during 18F-FDG PET/CT scans, this study found glucose levels were consistently high.
• The analysis shows alterations in glucose metabolism linked to cancer progression within this population.
• Highlighting the need for awareness of glucose levels during imaging, this may influence clinical evaluations.